MAPK3 and cardiac hypertrophy: We found that sarpogrelate suppressed PE-induced cardiomyocyte hypertrophy in a 5-HT2A receptor-independent manner by inhibiting the ERK1/2–GATA4 signaling pathway and by suppressing pressure overload-induced cardiac hypertrophy and systolic dysfunction in vivo.